Clinical Studies

Medical Academy Astrakhan (Russia): Patient’s Experiences Using the Deta-Ritm and Deta-AP

respiratoryThis survey was conducted under the supervision of a physician and Lecturer in the Academy of Aa Panob, Russia – 33 patients were examined with varying health issues; 23 children from 2 to 17 years and 10 adults from 30 to 59 years old.
There was a variety patients with an array of different health problems, including:

  • Upper respiratory infection: 4 patients
  • Herpes: 7 patients
  • Chronic Herpes: 7 patients
  • Tinea pedis (athlete’s foot): 1 patient
  • Nasopharyngitis (caused by Candida): 2 patients
  • Ostechondrosis of the cervical and thoracic spine: part 4 patients
  • Gastro-duodenitis: 5 patients
  • Dystonia: 2 patients
  • Diabetes mellitus: type 2 – 1 patients

The overall conclusion reached was that the combined treatments using the Deta-Ritm and Deta-AP devices had improved the overall health of 75% of the patient population after only 2-3 days of using the devices. The overall general effectiveness of all the treatments was 97%.

Patients generally tolerated the treatments without complaining about being inconvenienced as the treatments were mostly conducted in the patient’s home.

There were no side effects reported from any of these patients.

Gynaecological Survey – Medical College, Nizhny Novgorod (Russia): Effectiveness of Treatment with Deta-AP devices

gynecologyThis survey was conducted under the supervision of Professor B.E. Sachob, beginning on 04/09/2009.

100 women were examined, aged 18 to 42 years suffering from Pelvic Inflammatory Disease (PID) associated with infections such chlamydia, mycoplasmas, ureoplasma, Cytomegalovirus, herpes and HPV – these women were divided into 3 groups:

  1. Use of Deta-AP only
  2. The use of Deta-AP along with prescription medications
  3. The use of only prescribed medications

The highest effectiveness of treatments was when the Deta-AP was combined with prescribed medications (87 – 92%) and 85% effectiveness when the Deta-AP alone was used.

When using only prescribed medications such as antibiotics and antivirals, the effectiveness dropped to 60 – 65%.

It appears that the Deta-AP can clearly compliment prescribed medications and increase their effectiveness, even though the Deta-AP used by itself can still help 85% of these PID infections.

Pediatric Clinic No 2, Oyfa City (Russia) using the Deta-Ritm and Deta-AP in the treatment of children and adolescents with osteroporosis and osteopenia, as well as digestive problems

pediatricThis survey was conducted under the supervision of the Professor of the Department of Pediatrics of the State Medical University of the Republic of Bashkortostan, Southeast Ntroyzinin.

63 children were monitored, aged 12 to 15 years (43 girls and 20 boys). All these children underwent extensive testing and clinically diagnosed.

The children were divided into two groups:

  1. Treated for calcium metabolism disorders using the drug Calcemin
  2. Treated for calcium metabolism disorders using only the Deta-Ritm and Deta-AP devices; for ten consecutive days.

Effectiveness of Treatments (%)

Health Problems Deta-Ritm & AP Devices only Drug Calcemin
Pain, appetite, indigestion 93,2% 82.6%
Inflammation, action speed 87.7% 72,1%
Statistical Testing (T-Test) 91.6% 78.3%

The results showed that the group of children treated only with the Deta-AP and Ritm devices had a statistically significant difference – more effective – than the group that was treated only with the prescription drug Calcemin.

This was for the two major health issues of digestive problems and inflammation with pain.

Treating Intestinal Infections in Children Using the Deta-AP and Deta-Ritm devices: Paediatric Clinic of Salabat City (Russia)

gut problemsThis health survey was conducted under the supervision of Dr. Giatsenko Archiatroy and Dr. Fakoylinz, both paediatricians.

The investigation lasted six months in total from October 2009 to March 2010.

There was a total sample of 48 children, aged from 5 to 14 years old who were diagnosed with parasitic infestations of ascariasis and giardiasis, both common intestinal infections.

The children were divided into three groups:

  1. Treated only with prescription medication
  2. Treated only with the Deta-AP and Deta-Ritm devices
  3. Treated with prescription medications, as well as the Deta-AP and Deta-Ritm devices.

In the first group when only prescribed medication was used to eliminate these intestinal parasites, there was a 48% cure rate. In the second group where only the Deta-AP and Deta-Ritm devices were used, there was an 86% cure rate, while when both the devices and medications were combined there was a 94% cure rate.

The main disadvantages of using medications is that they have side effects that vary from patient to patient. The Deta-AP and Deta-Ritm devices however did not have any such side effects and were completey safe and easy to use with these children.

Male Urogenital Problems Treated with the Deta-AP and Deta-Ritm – Dr Tsernich (2001) – Borones (Russia)

male urogenitalMore than 2,000 patients with chronic prostatitis, prostate adenoma, chronic cystitis, nephritis, pyelonephritis, Glomerulonephritis, kidney stones and sexual dysfunctions were examined. There were a total of 3,849 diagnoses made using the Deta-Professional bioresoance diagnostic and treatment device.

Of these, 1,500 were actually treated with the Deta-AP and Deta-Ritm devices.

In the cases of chronic prostatitis (chronic inflammation of the prostate), when the Deta-AP and Deta-Ritm devices were used in combination with prescribed medication, the cure rate was 90%.

In the 200 patients with prostate adenoma, after 30 days treatment with the Deta-AP and Deta-Ritm devices, in combination with medication, the urinary flow rate and size of the prostate decreased significantly.

In the 500 patients with kidney inflammation, 10 treatments using the Deta devices were sufficient to completely reduce the inflammation.

In the 30 patients with kidney stones, these stones were no longer detectable after a minimum of 15 treatments using the Deta devices – some people would require more than 15 treatments to eradicate the kidney stones.

In conclusion, the use the Deta-AP and Deta-Ritm devices resulted in excellent results with male urogenital problems that may in some cases have required surgery.

Moscow’s Central Military Hospital – using Deta Devices in Medical Practice

This report was prepared on 17/11/1995 by the Consultant of the Central Military Hospital of Moscow, Dr. Betsoyk and Dr. Volkov.

peripheral nervous systemThis study included 20 patients aged 40 to 60 years with diseases of the peripheral nervous system (inflammation of the spinal nerve root), first and second stage hypertension, sleep disturbances and vasomotor rhinitis.

In some of these cases the patients had seen improvements after only one session with the Deta devices. In 80% of the cases there was considerable improvement and in 70% of the cases the blood pressure had normalized without using any other medication.

Another notable observation was the complete ameliation of pain in these patients. Insomnia was also improved considerably.

In this pilot study, it is clear that the Deta devices used alone can help many different neurological symptoms, as well as helping in cases of hypertension.

Pediatric Clinic No. 1, Borones (Russia) – effectiveness of the Deta-AP and Deta-Ritm devices on 341 Children with Various Diseases

asthma in childrenThe survey was conducted from March 2003 to April 2005 under the supervision of assistant consultant, Dr. Gkolopkoba and T.B. pediatrician Dr. Nteineka.

341 patients were treated with the Deta devices, aged from 7 to 15 years.

These 341 children were divided into 5 groups, as follows:

  1. Problems with vision (myopia, presbypoia and astigmatism) – 166 patients.
  2. Problems with gastrointestinal system (chronic inflammation of the duodenum, colitis, bile dyskinesia) – 18 patients.
  3. Autonomic Nervous System problems – 130 patients.
  4. Musculoskeletal problems (scoliosis and osteochondrosis of the vertebral column) – 18 patients.
  5. Respiratory problems (bronchial asthma, bronchitis) – 9 patients.

GROUPS HEALTH PROBLEMS PERCENTAGE IMPROVEMENT

  1. Vision problems 66%
  2. Gastrointestinal 98.7%
  3. Autonomic Nervous System 97.6%
  4. Musculoskeletal 46%
  5. Respiratory 94.6%

The improvements that many of these children had were really quite remarkable, given that the only treatment they received was with the Deta-AP and the Deta-Ritm – no other medication was used.

The Use of the DETA devices on school children in the Children’s Anti-tuberculosis Health Resort of the city of Ufa, Russia

Doctor G.T. Khalikova

ascarisThe aim of the tests was to evaluate the efficiency and safety of DETA-AP and DETA-RITM devices in a Children’s Anti-Tuberculosis Health Resort.

One DETA-AP device and one DETA-RITM device were used during all the tests.

Patients medically diagnosed using clinical testing with the following diseases were treated with DETA-AP device:

-  Ascariasis;

-  Enterobiasis;

-  Lambliosis.

The “Antihelmetic” program was used once per week for a period of one month. At the same time the children also received antihelminthic herbs from the root of sweet flag and wormwood tinctures.

Before running the “antihelmetic” programs, the Deta AP “Drainage” programme was run for 17 minutes.

Depending on the type of helminth the following Deta AP programmes were used:

Seatworm;

-  Ascarid;

-  General parasites.

All programmes were run for 35 minutes.

Lamblia programme was carried out twice during one month, run time of the program was 45 minutes.

Immediately after each “antihelmetic” programme, the  “drainage therapy” programme was run to help eliminate toxins related to the parasite die-off – run-time 17 minutes.

If after running the anti-parasite programme,  there were mild gastrointestinal tract symptoms, then the Deta Ritm programme for “gastrointestinal tract regulation” was used for 40 minutes.

The DETA-RITM was used mainly with children having gastroduodenitis, biliary dyskinesia and cholecystitis.

For all these cases, the “Active Defense” programme was used for 40 minutes initially.  The child would then take a break for an hour, and then the “gastrointestinal tract regulation” programme was used for 40 minutes. The child would then take another break for an hour, then the “Deep Cleaning” programme was used for 40 minutes.

All children were required to drink plenty of water to help the flushing of toxins – 30 ml. water to each kilo of body weight.

Here are examples of various programmes ran on the Deta AP for various parasites:

Set of programs to treat Ascariasis

  1. Drainage therapy – 17 minutes.
  2. Ascarids – 35 minutes.
  3. Repeat Drainage therapy – 17 minutes.

Set of programs to treat Lambliosis

  1. Drainage therapy – 17 minutes.
  2. Lamblias – 45 minutes.
  3. Repeat Drainage therapy – 17 minutes.

Set of programs to treat enterobiasis

  1. Drainage therapy – 17 minutes.
  2. Seatworms – 35 minutes.
  3. Repeat Drainage therapy – 45 minutes.

These treatment complexes for Ascariasis, Lambliosis and Enterobiasis was carried out one or two times per week for one month.

Set of programs to treat Gastroduodenitis and biliary Dyskinesia

  1. Active Defense mode
  2. 1-hour pause
  3. Gastrointestinal tract regulation
  4. 1-hour pause
  5. Deep cleaning 40 minutes.

This treatment complex was applied once a day for 30 days.

Set of programs to treat neurosis-like conditions (hyperactivity and excitability) of children

  1. Active Defense
  2. Blood circulation
  3. Gastrointestinal tract regulation
  4. Deep cleaning

This treatment complex was applied once per day for 20 consecutive days.

The Deta devices were used with children up to 4 years old – most of the children wore the devices over their clothes in their breast pocket.

Clinical Trials to Determine the Treatment Efficacy of the DETA-AP Therapy Devices for the treatment of Pelvic Inflammatory Disease (acute and chronic forms)

PIDThis research was designed to determine the efficacy of the DETA-AP therapy devices with patients suffering from a clinically diagnosed Pelvic Inflammatory Disease (PIF), associated with Chlamydia, Mycoplasma, Ureaplasma, Cytomegalovirus (CMV), herpes II, and Human Papillovirus (HPV).

There were three treatment groups:

1. GROUP 1 – took only antibiotic and antiviral prescribed medication for treating Chlamydia, Mycoplasma, Ureaplasma, Cytomegalovirus (CMV), herpes II, and Human Papillovirus (HPV).

2. GROUP 2 – A combined treatment using the same medications as above, along with the Deta AP therapy device.

3. GROUP 3 – Using only the Deta AP therapy device.

The 45 women taking part in these clinical trials were aged between 18-42 years (mean: 29 years) being treated on an outpatient basis in the maternity welfare centre № 10 of the Medical and Preventive Treatment Institution of “Maternity Hospital № 4” of Nizhny Novgorod State Medical Academy, Russia. The Principal Investigator was Prof. Borovkova, Head of Department, and Dr Pershin, Assistant Head.

All the woman included in the research had been clinically diagnosed with PID (both acute and chronic) and had clinical tests indicating the presence of chlamydia, mycoplasma, ureaplasma, CMV, herpes and HPV infections. The tests were conducted using enzyme multiplied immunoassay data and fragment detection of pathogen DNA by means of PCR.

The Local Ethical Committee of the State Health Care Institution of Nizhniy Novgorod District Clinical Hospital n.a. N.A. Semashko approved these clinical trials which were voluntary.

RESULTS:

The 45 women in the clinical group were divided into 2 groups:

  1. GROUP 1 – those that combined prescription medication with the Deta AP bioresonance therapy devices.
  2. GROUP 2 – those that used only the Deta AP bioresonance therapy devices

There was also a 3rd group of 55 women, aged 18 – 42 years, that received only prescribed medication.

The women using the Deta AP therapy devices ran them for an average of 40 – 60 minutes – there were three programmes ran every other day along with detoxification programmes.

There were frequent clinical examinations conducted to determine progress using clinical pelvic examination, ultrasound, thermography as well as blood analysis and microbiological assay of vaginal samples.

Table 1 below describes the influence of the various treatment modalities – it is clear that the average duration of using the Deta AP devices is only 3 days, versus an average of 8 – 25 days for using medications alone or medications in combination with the Deta device:

Table 1. The influence of the various treatment modalities

Diagnosis Quantity of Patients Average duration of treatment – medications and Deta devices (days) Average duration  of using only DETA-AP devices (days) Average duration of treatment using only medications (days)
Gp1 Gp2 Gp3
Clamydia 6 2 10 12.2±1.4 3±0 14.53±1.7
Mycplasmosis 3 2 9 7.23±1.1 3±0 8±1.3
Ureaplasmosis 6 2 10 8.93±0.9 3±0 9.33±1.1
CMV infection 6 3 8 10.73±1.2 3±0 12.23±1.5
HPV infection 5 3 10 14.43±1.3 3±0 15.93±1.3
Herpes virus 4 3 8 21.3±2.7 3±0 24.53±3.0

CONCLUSIONS:

It is interesting to note that the overall success of treatment using only prescribed medications was about 60 – 65%. This was for the treatment of the various microorganisms in question.

When the medications were combined with the use of the Deta AP device, the treatment outcome increased to 87 – 92%.

When the Deta AP device was used alone with no medications given, the treatment outcome was 85%.

The absence of any adverse side effects using the Deta AP devices resulted in the researchers concluding that bioresonance therapy was an excellent way of treating the underlying microbial caused of Pelvic Inflammatory Disease, either in the clinical setting or at home.

Testing the Efficacy of the DETA-AP devices as part of treating patients having Pulmonary Tuberculosis (TB)

TB2The aim of this clinical pilot study was to determine the efficacy of the Deta AP bioresonance devices with patients that had been clinically diagnosed with Pulmonary TB, including multiple drug-resistant TB.

The trials were conducted at the State Health Care Institution of the Yaroslavl Region Regional Clinical Hospital for Tuberculosis, Russia.

Twenty five patients having tuberculosis were tested, among them there were 11 women, 14 men and 9 of these patients had multiple drug-resistant tuberculosis.

The age of the men was from 24 to 56 years old, the women from 24 to 58 years old.

The Deta AP therapy programme “Tuberculosis” was run for the prescribed period of time, once per week for 30 days. Criteria for assessing the efficiency of treatment were clinical, radiological and bacteriological examinations.

Radiological improvements were observed in 18 cases (72%); a further 6 cases (24%) had no change and only 1 case got worse (4%).

According to the bacteriological examination, a complete eradication of the TB bacterium was seen in 12 cases (48%), BK (-) in 8 cases before and after the examination, with 4 patients that were still positive.

One patient had to terminate treatment after 4 sessions, as drug liver disease and hepato-renal syndrome developed.

It should be noted that all programmes of the devices are well-tolerated, and there were no adverse reactions to the treatment.

Conclusions

1. DETA-AP treatment is safe for TB infections.

2. The applied treatment protocols for TB should be further developed – increasing exposure time, multiple sessions, extending the duration of treatment from one month to 2-4 months.

Download the FREE Deta Widget APP and help us give you the latest updates!

Leave a Reply

Your Email Address:  *
First Name:
Enter the security code shown: *
Email marketing by Interspire




hmd.jpg